First, in the original description of the Tg-DN-Trx1 mouse11, it was reported that elevations in oxidative stress induced cardiac hypertrophy with taken care of cardiac function less than baseline conditions. inhibition of ASK1 signaling and HDAC4 nuclear export, which ultimately prospects to the attenuation of LV redesigning. In response to myocardial injury, the geometry, mass, volume, and function of the remaining ventricle (LV) switch during a process referred to as ventricular redesigning. Initially, this process is considered to be adaptive. However, in response to continuous stimuli following events such as myocardial infarction, LV redesigning becomes maladaptive leading to the development of heart failure.1 Moreover, the morphological and functional changes that go with LV remodeling serve as predictors of morbidity and mortality.2 Therefore, it is necessary to elucidate cellular and molecular mechanisms that underlie the development of heart failure so that pharmacotherapies designed to coincide with the standard means of care can be applied to improve the prognosis of individuals suffering from this debilitating disease3. In this regard, therapeutic strategies aimed at increasing the levels of hydrogen sulfide (H2S) have come to be a focus of interest given their ability to exert cytoprotective c-di-AMP effects in various models of injury. In the heart, treatment with exogenous H2S or modulation of the endogenous c-di-AMP production of H2S through the cardiac-specific overexpression of the H2S-generating enzyme, cystathionine -lyase (CSE), promotes cardioprotection against acute myocardial ischemia-reperfusion (I/R) injury and heart failure.4,5 In contrast, the pharmacological inhibition or genetic deficiency of CSE effects in an exacerbation of myocardial c-di-AMP injury.6,7 These and additional studies demonstrate that H2S utilizes a variety c-di-AMP of effects to counter ischemic injury, including its ability to attenuate oxidative pressure, inhibit apoptosis, FRAP2 and reduce inflammation.7 While these studies provide important insights into the cardioprotective actions of H2S, they have not fully investigated the cellular mechanisms that underlie these cytoprotective effects. Thioredoxin 1 (Trx1) is an oxidoreductase enzyme that functions as an antioxidant by facilitating the reduction of additional proteins by cysteine thiol-disulfide exchange.8 Through its redox activity Trx1 regulates apoptosis signal-regulating kinase-1 (ASK1), nuclear element B, Ras, and Akt.9 Individuals with acute coronary syndrome and dilated cardiomyopathy show elevated serum levels of Trx1 suggesting a possible association between Trx1 and the severity of heart failure.10 Experimental studies demonstrate that Trx1 plays a pro-survival role in response to myocardial injury. This is attributed to its ability to reduce cardiac hypertrophy in models of heart failure11,12 and to reduce apoptosis in models of heart failure13 and I/R injury.14 Therefore, Trx1 is an ideal cellular target for impeding the progression of heart failure. H2S offers previously been shown to increase the protein manifestation of Trx1 following a solitary injection.4 Based on this evidence and the evidence that Trx1 takes on a protective part in the heart, one can speculate that Trx1 contributes to the cardioprotective mechanisms of H2S. Consequently, a major goal of this study was c-di-AMP to determine if Trx1 mediates the cardioprotective effects of H2S inside a model of ischemic-induced heart failure. Results Na2S Treatment Limited the Extent of Myocardial Injury Following Heart Failure Initial experiments were conducted to investigate the degree of myocardial injury and the effects of H2S in the ischemic heart failure model. For these experiments, mice were subjected to 60 moments of LCA ischemia followed by 4 weeks.